-

Foundation Medicine Drives Awareness on the Importance of Quality and Accuracy in Cancer Biomarker Testing

Quality First initiative features patient advocate stories and educational assets to create awareness on how not all cancer biomarker tests are created equal

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, announced today the launch of a new initiative aimed at driving awareness about the importance of high-quality biomarker testing in cancer care. Quality First educates on the role biomarker testing plays in supporting treatment decision-making and how the accuracy and clarity of these tests can impact patients’ being matched to an effective treatment option.

“At Foundation Medicine, we are transforming the future of cancer care through high-quality biomarker tests and services,” said Foundation Medicine Senior Vice President of Corporate Affairs Jennifer Romans. “Cancer is complex, and it requires a personalized, data-driven approach to enable confident care decisions. Not all biomarker tests are created equal and precision cancer care can only be as good as the quality and accuracy of the tests used to inform treatment.”

Quality First spotlights stories from patient advocates about the role high-quality biomarker tests have played in their treatment planning, as well as educational videos, a glossary of important biomarker testing terms, among other assets.

“Patients care about test quality, because we know that accuracy is the key to unlocking the right treatment options,” says Karen Peterson, breast cancer patient advocate. “A Foundation Medicine biomarker test detected my tumor mutational burden-high status making me eligible for a clinical trial.”

“As a patient navigating cancer, everything can seem unclear and overwhelming. We need to have accurate information presented in a way that is understandable to make informed decisions,” says Greg Wehn, non-small cell lung cancer patient advocate. “High-quality biomarker tests like Foundation Medicine’s generate reports that distill complex results in a clear way, which helps inform how your healthcare team builds your individualized treatment plan.”

For more information, visit FoundationMedicine.com/QualityFirst.

About Foundation Medicine

Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com and follow us on LinkedIn, X, YouTube, Facebook, Instagram and BlueSky.

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Contacts

Holly Campbell, 480-213-8368
newsroom@foundationmedicine.com

Foundation Medicine


Release Summary
Foundation Medicine launches Quality First, an initative to drive awareness about the importance of high-quality biomarker testing in cancer care.
Release Versions

Contacts

Holly Campbell, 480-213-8368
newsroom@foundationmedicine.com

More News From Foundation Medicine

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for Itovebi™ (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant. Itovebi is a therapy developed by Genentech, a member of the Roche group, which is approved for the treatment of adult patients with endocrine-resistant,...

Foundation Medicine and SWOG Clinical Trials Partnerships Announce Strategic Collaboration to Advance Biomarker-Driven Research and Clinical Trials

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, and SWOG Clinical Trials Partnerships (SWOG CTP) today announced a strategic partnership to advance biomarker-driven research and clinical trials, marking the first collaboration of this nature with a diagnostic company. This partnership builds upon Foundation Medicine’s decade-long collaboration with SWOG Cancer Research Network through the Lung Cancer Master Protocol (Lung-MAP) trial, a m...

US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRP...
Back to Newsroom